These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 22763975)
1. The role of leukotrienes in the pathogenesis of systemic sclerosis. Chwieśko-Minarowska S; Kowal K; Bielecki M; Kowal-Bielecka O Folia Histochem Cytobiol; 2012 Jul; 50(2):180-5. PubMed ID: 22763975 [TBL] [Abstract][Full Text] [Related]
2. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832 [TBL] [Abstract][Full Text] [Related]
3. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Kowal-Bielecka O; Distler O; Neidhart M; Künzler P; Rethage J; Nawrath M; Carossino A; Pap T; Müller-Ladner U; Michel BA; Sierakowski S; Matucci-Cerinic M; Gay RE; Gay S Arthritis Rheum; 2001 Aug; 44(8):1865-75. PubMed ID: 11508440 [TBL] [Abstract][Full Text] [Related]
4. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Kowal-Bielecka O; Chwiesko-Minarowska S; Bernatowicz PL; Allanore Y; Radstake T; Matucci-Cerinic M; Broen J; Hesselstrand R; Krasowska D; Riemekasten G; Vonk M; Kowalczuk O; Bielecki M; Milewski R; Chyczewski L; Niklinski J; Kowal K Rheumatology (Oxford); 2017 May; 56(5):844-852. PubMed ID: 28160477 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. Kowal-Bielecka O; Kowal K; Distler O; Gay S Nat Clin Pract Rheumatol; 2007 Jan; 3(1):43-51. PubMed ID: 17203008 [TBL] [Abstract][Full Text] [Related]
15. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Devillier P; Baccard N; Advenier C Pharmacol Res; 1999 Jul; 40(1):3-13. PubMed ID: 10378985 [TBL] [Abstract][Full Text] [Related]
16. An update on biomarker discovery and use in systemic sclerosis. Matsushita T; Takehara K Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919 [TBL] [Abstract][Full Text] [Related]
17. Type I interferon dysregulation in Systemic Sclerosis. Skaug B; Assassi S Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202 [TBL] [Abstract][Full Text] [Related]
19. Role of Alarmins in the Pathogenesis of Systemic Sclerosis. Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721 [TBL] [Abstract][Full Text] [Related]
20. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Zhu H; Luo H; Zuo X Exp Mol Med; 2013 Sep; 45(9):e41. PubMed ID: 24052166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]